Abstract 3457
Background
With immunotherapy (IO) being the standard of care in melanoma, over time this has led to pressures within the medical day unit (MDU), especially as other cancer algorithms have evolved incorporating IO. Main pressures include reduced capacity, increasing patient numbers leading to greater pressure on doctors and requiring greater consultation time with patients to discuss survivorship issues. To help address these issues a pharmacist and nurse (P/N) led clinic was created as a new model of care in 2017.
Methods
Melanoma patients prescribed IO are placed into the clinic and reviewed 2-4 weekly as per IO regimen. Doctors review patients 12 weekly in outpatients for scan results. To assess the benefit of the clinic the number of referrals made back to the doctor before 12 weeks were recorded. Consultations needing >10 mins to discuss survivorships issues and P/N interventions were recorded.
Results
36 patients (age 24-89 yrs) have been referred to the clinic; 33 needed IO treatment, 2 steroid weaning and 1 temozolomide patient, needing nursing support. All patients required clinical evaluation for consideration of next cycle. Doctor’s input was required for 4 patients; 2 for inpatient admission for IO toxicity (monitoring for adrenal insufficiency, diabetic ketoacidosis), 1 for a biopsy (new skin nodule), 1 (scan results). Interventions routinely made by P/N included referrals to surgeons (3), dermatologist (2), ophthalmologist (2), tissue viability nurse (2), lymphedema team (2), physiological support (2) and fitness instructor (2). All patients required survivorship support and consultations ranged from 15-45 min. Common themes which emerged included how to partake in physical activity, anxiety on stopping IO, financial burden and advice on complementary therapies. In the melanoma team patients stop IO at 2yrs. Discussion on stopping IO is explored within 3 months of stopping IO; this discussion has occurred in 18/33 patients, in which the P/N helped alleviate patient’s anxiety over this time.
Conclusions
The clinic has become embedded within the melanoma service and has helped improve MDU pressures by removing patients requiring greater holistic support. This clinic in turn has sought out survivorship issues important to melanoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract